Drug intelligence / Profile preview

LY3192767

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous

Overview

LY3192767 is an investigational small molecule drug developed by Eli Lilly. It has been studied in healthy participants and is administered subcutaneously[1][3]. The mechanism of action is not fully established in public sources, but one source suggests it may act as a Beta-secretase 1 inhibitor to reduce beta-amyloid production, which would be relevant for Alzheimer's disease[8]. However, this mechanism is not confirmed across all sources. No approved indications or marketed brand names are known.

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on LY3192767.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3192767.

Explore the full profile